IME Price sensitive 26 Sep 2025, 8:27 AM

IMEXHS signs new radiology services contract

Imexhs Ltd

IMEXHS signs new radiology services contract

Key points

  • Radiology services contract with Oncolife, a leading cancer-focused healthcare provider in Colombia
  • Provision of radiology services supported by IMEXHS' RIS/PACS platform, patient portal, and AI diagnostic layers
  • Initial term of one year, expected to contribute A$1.4 million in New Annual Recurring Revenue

Full summary

IMEXHS Limited (ASX: IME) has entered into a radiology services contract with Oncolife, a leading cancer-focused healthcare provider in Colombia. Oncolife operates a hospital in north Bogotá as its main site, with additional centres in Villavicencio and Zipaquirá, all dedicated to the treatment of cancer patients and requiring high-complexity diagnostic procedures, including advanced radiology services. Under the contract, IMEXHS will provide radiology services to Oncolife's network, supported by the deployment of IMEXHS' RIS/PACS platform, patient portal, and selected AI diagnostic layers. The initial term of the contract is one year, commencing immediately, and is expected to contribute approximately A$1.4 million in New Annual Recurring Revenue (NARR), which includes both radiology services and software revenue. The contract operates under the Company's new pricing structure implemented in 2024. IMEXHS CEO Dr Germán Arango commented that the agreement underscores the strength of the company's radiology services offering in high-complexity care, supported by its integrated software solutions and AI modules, and demonstrates the effectiveness of its new pricing model to deliver improved profitability alongside growth. This contract further consolidates IMEXHS's position as a leading provider of radiology services in Latin America and supports the Company's strategy of expanding high-value partnerships in specialised healthcare segments.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in